文献速递浆细胞疾病造血干细胞移植与细胞治疗

BCMA-mRNA疫苗是多发性骨髓瘤有前景的治疗手段

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.
PubMed 文献 · Blood · 2025-01-01

研究利用脂质纳米颗粒(LNP)包裹序列和碱基优化的BCMA mRNA,并共包裹TLR3激动剂聚肌胞苷酸[poly(I:C)],体外可被树突状细胞摄取并激活BCMA特异性CD8+细胞毒性T细胞,后者可裂解BCMA+ U266骨髓瘤细胞和CD138+患者骨髓瘤细胞;小鼠接种后诱导BCMA特异性CTL并抑制肿瘤生长,联合poly(I:C)进一步增强免疫应答。

要点

  • BCMA-mRNA LNP疫苗体外激活BCMA特异性CD8+ CTL并裂解BCMA+骨髓瘤细胞。
  • C57BL/6J小鼠接种后诱导脾DC活化和BCMA特异性CTL。
  • 荷瘤小鼠接种抑制肿瘤生长,联合poly(I:C)进一步增强免疫应答。

核心结论

  • BCMA-mRNA LNP疫苗联合poly(I:C)可诱导BCMA特异性CD8+ T细胞应答并抑制小鼠骨髓瘤生长,为临床评估提供框架。

研究设计与样本

  • 研究为临床前体外与小鼠体内实验,使用BCMA mRNA-LNP疫苗及共包裹poly(I:C)的LNP制剂。

主要发现

  • BCMA-mRNA LNP体外被树突状细胞内化,触发BCMA特异性CD8+ CTL增殖和活化。
  • 这些CTL裂解BCMA+ U266骨髓瘤细胞和CD138+患者骨髓瘤细胞,不影响BCMA敲除U266或CD138-患者来源骨髓细胞。
  • C57BL/6J小鼠接种BCMA-mRNA LNP后激活脾脏DC并诱导BCMA特异性CTL,选择性杀伤过表达BCMA的鼠5TGM1骨髓瘤细胞。
  • 接种BCMA过表达5TGM1细胞的C57BL/KaLwRijHsd小鼠中,疫苗抑制肿瘤生长并伴随BCMA特异性CD8+ T细胞应答。
  • 在所有情况下,联合poly(I:C)进一步触发BCMA-mRNA LNP诱导的免疫应答。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cancer vaccines are emerging as promising therapies to not only prevent cancer but to treat cancer. Here, we developed a therapeutic vaccine for multiple myeloma (MM) using B-cell maturation antigen (BCMA) protein as a target. Given the remarkable efficacy of COVID-19 messenger RNA (mRNA) vaccines, we first packaged sequence- and base-optimized BCMA mRNA into lipid nanoparticles (LNPs) using next-generation ionizable lipid, enhancing their accumulation in the spleen. A toll-like receptor 3 agonist, polyinosinic:polycytidylic acid [poly(I:C)], was also encapsulated in LNPs to further elicit BCMA-specific immune response. BCMA-mRNA LNPs were internalized by dendritic cells (DCs) in vitro, triggering proliferation and activation of BCMA-specific CD8+ cytolytic T cells (CTLs). Importantly, these CTLs lysed BCMA+ U266 MM cells and CD138+ patient MM cells, without affecting BCMA-knockout U266 or CD138- patient-derived bone marrow cells. Vaccination of C57BL/6J mice with BCMA-mRNA LNPs activated splenic DCs and induced BCMA-specific CTLs, assessed by tetramer staining, which selectively killed murine 5TGM1 BCMA overexpressing MM cells. Finally, vaccination of C57BL/KaLwRijHsd mice bearing BCMA-overexpressing 5TGM1 cells inhibited tumor growth associated with BCMA-specific CD8+ T-cell responses. The combination treatment with poly(I:C) further triggered the immune response induced by BCMA-mRNA LNPs in all instances. Our findings provide the framework for clinical evaluation of BCMA-mRNA LNP vaccines to improve patient outcome in MM.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Dutta D, Liu J, Wen K, et al. A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma. Blood. 2025. PMID: 40700574. doi:10.1182/blood.2025028597

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。